Navigation Links
Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
Date:10/1/2009

CALGARY, Oct. 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Friday, October 2, 2009 at 6:30 a.m. MT (8:30 a.m. ET) to update investors on the Company's Phase 3 program for REOLYSIN(R).

To access the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2828320 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through October 9, 2009. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 4169017 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations as to the Phase 3 program for REOLYSIN, and the potential of REOLYSIN as a
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
2. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
3. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
4. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
5. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
6. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
7. Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
11. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... at the University of Central Florida have developed a ... more sensitive tool to detect pathogens associated with inflammatory ... nanoparticle-based technique also may be used for detection of ... they hide deep in human tissue and are able ...
... 2012 Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company ... offer shares of its common stock and warrants to purchase ... The offering is subject to market and other conditions, and ... the offering may be completed, or as to the actual ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
Cached Biology Technology:UCF scientists use nanotechnology to hunt for hidden pathogens 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/8/2014)... OhioThe future health of the world,s coral reefs and ... on the ability of one tiny symbiotic sea creature ... of algae it cooperates with. , In the first ... University discovered that coralstiny reef-forming animals that live symbiotically ... of heat stress, called "bleaching," when they keep large ...
(Date:7/8/2014)... Think of your next exercise workout as a "fun run" or ... of it as exercise or as a workout and you,ll later ... findings from the Cornell Food and Brand Lab study involved two ... a small lake and were either told it was going to ... the first study, 56 adults completed their walk and were then ...
(Date:7/8/2014)... NY, July 8, 2014Novel oligonucleotide-based drugs in development ... diseases. A group of industry and regulatory scientists ... recommendations for evaluating the pharmacological safety of oligonucleotide ... Acid Therapeutics , a peer-reviewed journal from Mary ... on the Nucleic Acid Therapeutics ...
Breaking Biology News(10 mins):For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... issue of G&D report on the discovery of ... The studies from Drs. Alexander Stark and Manolis ... Lai (MSKCC) and colleagues, both reveal that antisense ... the novel miRNA precursor mir-iab-8, which is processed ...
... doctors treating life-threatening emergencies such as allergy attacks may give ... Adrenaline is stored in salt water in glass ampoules ... The amount of adrenaline contained in the ampoule is usually ... per 1 mL of salt water) and a ratio (1 ...
... team at Weill Cornell Medical College in New York City ... production of an immune system cytokine called interleukin-10 (IL-10). ... in a biochemical pathway that,s long been tied to disorders ... AIDS. "IL-10 production has to be kept in a ...
Cached Biology News:Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 22 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3
... Unique, compact measuring instrument for calibrating single-channel ... design and the robust carrying case, the ... in the laboratory and on-site at the ... to use because the individual channels are ...
... DTT White solid.. PACKAGED UNDER INERT ... so reaction is "driven" to completion. A protective ... surfactant found in many other preparations. Blocks the ... ≥97% by titration. Contaminants: Heavy metals: ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... Basically, most ``special`` dye stains ... a few other non-routine) stains are ... of a paraffin block, staining, coverslipping ... Stain (for senile plaques) ,Bodian`s Stain ...
Biology Products: